We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
FDA hopes to continue increasing the number of drug approvals while speeding up review times this year using a three-pronged strategy it adopted last year, the agency announced Jan. 15.
Generic firm Andrx announced it has received conditional approval from the FDA for its new mania and seizure treatment valproate delayed-release tablets, which is similar to brand firm Abbott Laboratories’ profitable drug Depakote.